- Home
- CANF vs FTAIM Comparison
CANF vs FTAIM Comparison
Compare CANF & FTAIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- FTAIM
- Stock Information
- Founded
- CANF 1994
- FTAIM N/A
- Country
- CANF Israel
- FTAIM United States
- Employees
- CANF N/A
- FTAIM 580
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- FTAIM Misc Corporate Leasing Services
- Sector
- CANF Health Care
- FTAIM Industrials
- Exchange
- CANF Nasdaq
- FTAIM Nasdaq
- Market Cap
- CANF 7.9M
- FTAIM N/A
- IPO Year
- CANF N/A
- FTAIM N/A
- Fundamental
- Price
- CANF $1.15
- FTAIM $25.46
- Analyst Decision
- CANF Strong Buy
- FTAIM
- Analyst Count
- CANF 2
- FTAIM 0
- Target Price
- CANF $14.00
- FTAIM N/A
- AVG Volume (30 Days)
- CANF 423.1K
- FTAIM N/A
- Earning Date
- CANF 05-06-2025
- FTAIM N/A
- Dividend Yield
- CANF N/A
- FTAIM N/A
- EPS Growth
- CANF N/A
- FTAIM N/A
- EPS
- CANF N/A
- FTAIM N/A
- Revenue
- CANF $674,000.00
- FTAIM N/A
- Revenue This Year
- CANF $461.72
- FTAIM N/A
- Revenue Next Year
- CANF N/A
- FTAIM N/A
- P/E Ratio
- CANF N/A
- FTAIM N/A
- Revenue Growth
- CANF N/A
- FTAIM N/A
- 52 Week Low
- CANF $1.22
- FTAIM N/A
- 52 Week High
- CANF $4.69
- FTAIM N/A
- Technical
- Relative Strength Index (RSI)
- CANF 35.40
- FTAIM 48.76
- Support Level
- CANF $1.14
- FTAIM $25.45
- Resistance Level
- CANF $1.27
- FTAIM $25.74
- Average True Range (ATR)
- CANF 0.12
- FTAIM 0.37
- MACD
- CANF -0.02
- FTAIM 0.05
- Stochastic Oscillator
- CANF 0.00
- FTAIM 76.61
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About FTAIM FTAI Aviation Ltd. 9.500% Fixed-Rate Reset Series D Cumulative Perpetual Redeemable Preferred Shares
FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.